Summary The effect of pravastatin, an inhibitor of p21 ras isoprenylation, on hepatocarcinogenesis induced by N-nitrosomorpholine and on p2l s isoprenylation were investigated in male Sprague-Dawley rats. Rats received i.p. injections of pravastatin (10 and 20 mg kg-1 body weight) every other day and, from the beginning of the experiment, were given drinking water containing N-nitrosomorpholine for 8 weeks. Vesible white nodules and hepatic lesions staining positively for gamma-glutamyl transpeptidase or glutathione-S-transferase, placental type, were examined macroscopically or histochemically. In week 15, pravastatin at both dosages significantly reduced the incidence, number and volume of visible white nodules. Quantitative histological analysis also showed that prolonged administration of pravastatin at both dosages resulted in significant reductions in the number and percentage area of hepatic lesions positive for gamma-glutamyl transpeptidase and glutathione-S-transferase, placental type. Administration of pravastatin also significantly decreased the amount of membrane-associated p21 ras in the tumour and the labelling index of neoplastic nodules and increased the apoptoic indices of neoplastic nodules. These findings indicate that pravastatin suppresses hepatocarcinogenesis and suggest that this effect might be related to pravastatin's inhibition of p21 ras isoprenylation and its subsequent inhibition of cell proliferation and induction of apoptosis in neoplastic lesions.
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Keywords: pravastatin; p21 ras isoprenylation; hepatocarcinogenesis; N-nitrosomorpholine Activating mutations of the K-ras gene have been detected in human hepatocellular carcinomas (Gu et al. 1986 ). Recently we found H-ras mutation of hepatic neoplastic lesions induced by N-nitrosomorpholine (Baba et al, 1997) . The ras-encoded protein p21 is localized at the plasma membrane, where it plays a key role in signal transduction (Grand and Owen, 1991; Egan and Weinberg, 1993; McCormick, 1993) . The membrane association and function of p21 are dependent on a series of post-translational processing steps, including isoprenylation (Sinensky et al, 1990) ; the biosynthesis of polyisoprenoids involved in p2lras processing is part of the mevalonate pathway of cholesterol synthesis. Pravastatin is an inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase, a rate-limiting enzyme that regulates the biosynthesis of cholesterol (Kawata et al, 1994) . This drug can inhibit p21ras isoprenylation and membrane localization (Kawata et al, 1994) . Narisawa et al (1994) found that pravastatin suppresses development of colon cancers induced by 1,2-dimethylhydrazine in female ICR mice. However, there are no reports of its effect on experimental hepatocarcinogenesis. Therefore, in the present work, we examined the effect of pravastatin on the development of hepatic lesions induced by N-nitrosomorpholine (NNM) in Sprague-Dawley rats.
MATERIALS AND METHODS Animals
Sixty young (6-week-old) male Sprague-Dawley rats were purchased from Japan SLC (Shizuoka, Japan). The animals were housed in suspended, wire-bottomed metal cages in animal quarters with controlled temperature (21-22°C), humidity (30-50%) and light (12-h cycle), and had free access to regular chow pellets (Nihon-Nosan, Yokohama, Japan).
Experimental design
After the acclimation for 1 week, animals were randomly divided into three groups of 20 rats each and treated as follows: group 1, the control group, was given 0.9% sodium chloride solution only i.p. every other day until the end of the experiment in week 15. From the beginning of the experiment, animals were also given drinking water containing 175 mg 1-1 of NNM (Sigma, St Louis, MO, USA) for 8 weeks. The NNM was dissolved in distilled water at a concentration of 50 g l-1 and stored in a cool place. The stock solution was diluted to 175 mg 1-1 with tap water just before use and supplied to rats from the bottles with renewal every other day. From week 9 onwards, rats were given normal tap water only, until the end of the experiment. From the beginning of the experiment, groups 2 and 3 received i.p. injections of pravastatin (a gift from Sankyo, Tokyo, Japan) at doses of 10 mg kg-' and 20 mg kg-' body weight, respectively, in 0.9% sodium chloride solution every other day until the end of the experiment in week 15. The rats in groups 581 2 and 3 were also given NNM for 8 weeks in the same way as group 1. Injections were given i.p. in a volume of 2 ml kg-' body weight, between 1400 and 1500 hours.
Macroscopical, histological and histochemical observations of hepatic lesions
In week 15, the non-fasted rats were all killed by ether anaesthesia between 1400 and 1500 hours. On the horizontally sliced liver specimens, white nodule formation was observed macroscopically. The counts of white nodules per rat were measured by slicing the entire liver at close intervals and recording the number of liver tumour per liver. Then 2-or 3-mm-thick liver sections obtained from the left and middle lobes were fixed in cold acetone (0-4'C) for 6 h and embedded in paraffin. Serial sections of 3 ,um thickness were stained with haematoxylin and eosin, gamma-glutamyl transpeptidase (GGT), using the procedure of Ruttenberg et al (1969) , or glutathione-S-transferase, placental type (GST-P), using the immunohistochemical peroxidase-antiperoxidase (PAP) method described by Stemnberg et al (1970) using anti-rat GST-P rabbit serum (Bio Prep Medlabs, Stillogan, Ireland) . Figure 1 Incidence, number and volume of visible white nodules in groups 1 (sodium chloride), 2 (pravastatin at 10 mg kg-') and 3 (pravastatin at 20 mg kg-') at week 15. Bars show s.e. Difference compared with group 1 was statistically significant: *P < 0.05, **P < 0.02, ***P < 0.01, ****P < 0.001 Measurement of enzyme-altered hepatic lesions Serial sections were scored for GST-P-positive and GGT-positive lesions without knowledge of their groups of origin. Only hepatic lesions 0.2 mm or more in greatest diameter in the plane of transection were counted, as reproducible evaluation of lesions less than 0.2 mm in diameter was impossible. The transectional area of lesions in the plane of tissue section and the area of the entire liver section were measured with an LA-500 Personal Image Analyzer System (Pias, Tokyo, Japan). In calculating the two-dimensional focus stereology, the area of liver occupied by hepatocellular carcinomas was subtracted. lesions in the liver of groups 1 (sodium chloride), 2 (pravastatin at 10 mg kg-') and 3 (pravastatin at 20 mg kg-') at week 15. Bars show s.e. Difference compared with group 1 was statistically significant: *P < 0.05, **P < 0.02, ***P < 0.01
Measurement of labelling index
The labelling indices of the neoplastic nodules and the surrounding liver were examined in week 15. The labelling index was measured with an immunohistochemical analysis kit for assaying bromodeoxyuridine (BrdU) incorporation (Gratzner, 1982; Morstyn et al, 1983 ) (Becton-Dickinson, Mountain View, CA, USA). For this purpose, five unstarved rats in each group of 
Measurement of apoptotic index
The apoptotic indices of the neoplastic nodules were examined at week 15. The apoptotic index was measured with an in situ apoptotic detection kit (Oncor, Gaithersburg, MD, USA) for assaying apoptotic cells by direct immunoperoxidase detection of digoxigeninlabelled genomic DNA in 5-jm sections of fixed tissue obtained from the liver of rats (Schmitz et al, 1991 Figure 5 Membrane-associated p21 -in visible white nodules, serum cholesterol levels, labelling indices and apoptotic indices of hepatic neoplastic lesions and adjacent liver of groups 1 (sodium chloride), 2 (pravastatin at 10 mg kg-') and 3 (pravastatin at 20 mg kg-') at week 15. Bars show s.e. Difference compared with group 1 was statistically significant: *P < 0.05, **P < 0.01, ***P < 0.001
Figure 6 Effect of pravastatin on p21 analysed by Western blotting in groups 1 (sodium chloride, right) and 3 (pravastatin at 20 mg kg-'1 left). C-p2l and M-p2l were cytosolic and membrane-associated isoprenylated p21 respectively
Statistical analysis
Results were analysed using the Chi-square test, Fisher's exact probability test or one-way analysis of variance with Dunn's multiple comparison (Siegel, 1956; Snedecor and Cochran, 1967; Miller, 1996 Pravastatin suppression of NNM hepatocarcinogenesis 585 A B Figure 7 Immunohistochemical photographs of hepatic neoplastic lesions from a control rat (A) and a rat treated with pravastatin at 20 mg kg-' body weight (B) at week 15. Apoptosis was more frequently found in a rat treated with pravastatin. Bar = 100 ,um
RESULTS

Body and liver weights
In week 15, no significant differences were found in the body weight, liver weight and relative liver weight among the three groups.
Number and size of visible white nodules and enzyme-altered lesions
In group 1, visible white nodules were found in 16 (80%) of 20 rats, and the average number and volume of white nodules were 3.4 ± 0.3 per rat and 215 ± 28 mm3 respectively (Figure 1) . However, prolonged administration of pravastatin at doses of 10 mg kg-' (group 2) and 20 mg kg-' (group 3) significantly reduced the incidence, number and volume of white nodules. Microscopically, almost all of the white nodules were hepatocellular carcinomas. Figure 8 Immunohistochemical photographs of hepatic neoplastic lesions from a control rat (A) and a rat treated with pravastatin at 20 mg kg-1 body weight (B) at week 15. Bromodeoxyuridine-labelled cells were less frequently found in a rat treated with pravastatin. Bar = 100 gm
The two-dimensional data showed that GST-P-positive lesions and GGT-positive lesions were significantly fewer (inhibition 18-21% for GST-P-positive lesions, 19-29% for GGT-positive lesions) and smaller (as a percentage of the parenchyma: inhibition 26-28% for GST-P-positive lesions, 36-46% for GGT-positive lesions) in groups 2 (pravastatin at 10 mg kg-') and 3 (pravastatin at 20 mg kg-') than in group 1 (sodium chloride only) (Figures 2 and 3) .
Immunohistochemically, of 294 neoplastic lesions visible on haematoxylin and eosin, 189 (64%) were positive for both GST-P and GGT, 51 (18%) were positive for GGT but not positive for GST-P, nine (3%) were positive for GST-P but not positive for GGT, and 45 (15%) were not positive for either GST-P or GGT (Figure 4 ).
Membrane-associated p21lmS labelling indices, apoptotic indices and serum cholesterol levels Treatment with pravastatin at 10 mg kg-' (group 2) and 20 mg kg-' (group 3) significantly reduced the production of membraneassociated p2lraS (inhibition 19% in group 2, 20% in group 3)
British Journal of Cancer (1998) compared with that in group 1 (Figures 5 and 6) . Furthermore, rats in groups 2 (pravastatin at 10 mg kg-') and 3 (pravastatin at 20 mg kg-') had significantly lower labelling indices for neoplastic nodules (inhibition 47% in group 2, 43% in group 3) and adjacent hepatocytes (53% in group 2, 73% in group 3) than rats in control group 1 (Figure 7 ). Pravastatin at 10 mg kg-' (group 2) and 20 mg kg-' (group 3) significantly increased the apoptotic indices for neoplastic nodules (enhancement 165% in group 2, 190% in group 3; Figure 8 ) and hepatocellular carcinomas (269% in group 2, 335% in group 3). However, pravastatin at both dosages had no effects on serum cholesterol levels.
DISCUSSION
The HMG-CoA reductase inhibitors are a new and novel class of cholesterol-lowering agents that are used worldwide (Robinson et al, 1994) . However, these drugs have cytostatic effects on proliferating cells in culture (Goldstein et al, 1979; Habenicht et al, 1980; Fairbanks et al, 1981; Maltese, 1984) . Recently, Morris et al (1995) found that lovastatin slows growth of hepatoma tissue culture-4 (HTC-4) cells at low concentrations. Lovastatin also slows cell growth in vivo (Maltese et al, 1985) . Sumi et al (1992) observed that growth of pancreatic carcinoma xenografts (CAV and H2T) in nude mice is inhibited by s.c. injection of lovastatin. Kawata et al (1992) reported that i.p. injections of pravastatin improve survival of AH-130 hepatoma-bearing rats and inhibits growth of ascitesforming tumours. Moreover, Narisawa et al (1994) observed that prolonged administration of pravastatin and simvastatin significantly reduces the number per mouse but not the incidence of colon tumours induced by 1,2-dimethylhydrazine in female ICR mice.
Our present results show that long-term administration of pravastatin significantly reduces the incidence of visible white nodules and suppresses development of enzyme-altered hepatic lesions induced by NNM in Sprague-Dawley rats.
Although the exact mechanism by which pravastatin suppresses hepatocarcinogenesis is still unclear, at least two possible explanations can be considered. One is an inhibition of the isoprenylation processing of ras protein (Dalton et al, 1995) . The p2lras protein is synthesized as a cytosolic precursor that is localized to the inner plasma membrane only after it undergoes a series of post-translational modifications, including farnesylation and methylation (Lowry and Willumsen, 1993) . The activity of p2lrLu is dependent on its localization to the inner plasma membrane. As a consequence, ras is dependent on farnesylation to function. Confirmation that ras requires prenylation to be active has been achieved by blocking farnesylation, either by mutation of the CAAX box cystein or by the treatment of cells with inhibitors of mevalonate synthesis. In both instances, oncogenic p2lras loses the ability to transform cells when prenylation is blocked (Cox and Der, 1992) . Kawata et al (1994) examined the effect of a combination of pravastatin and d-limonene (an inhibitor of protein isoprenylation) on cell growth of Hep G2, a human hepatoma-derived cell line, and found that production of membrane-associated p21rau is decreased to 35% of the control level. Ura et al (1994) observed that DNA synthesis, assayed in terms of [3H]thymidine uptake, isoprenylation of p2lras examined with Western blotting and cell progression from the G, to S-phase of the cell cycle analysed with flow cytometry in human and hamster pancreatic carcinoma cell lines are all inhibited by simvastatin. In the present work, we found that prolonged administration of pravastatin causes a significant decrease in membrane-associated p21r-in visible white nodules.
A second possibility is the inhibition of other pathways affected by pravastatin, such as cholesterol biosynthesis (Buchwald, 1992) . DeClue et al (1991) observed that inhibition of cell growth in vitro by lovastatin was not specific for cells whose transformation is dependent upon isoprenylated ras protein and suggested that other pathways are responsible for the growth inhibition by lovastatin. Sumi et al (1991) found that lovastatin inhibits cell growth of the human pancreatic cell line CAV by 78%, but the CAV cell line does not have a mutation in either H-or N-ras genes. They concluded that lovastatin's inhibition of pancreatic cell growth is not directly dependent on the presence of the ras mutation. Moreover, Herold et al (1995) observed that lovastatin markedly and dose-dependently inhibits proliferation of cultured enterocytes (CaCo-2), and that this suppression was reversed by the addition of either exogenous free cholesterol, endogenous cholesterol from mevalonolactone, or low-density lipoproteins. In the present study, however, we found that pravastatin at both dosages had no effects on serum cholesterol levels.
The ratio of labelling index of the neoplastic nodules to that of the adjacent liver was 4, 4.6 and 8.5 for groups 1 (sodium chloride), 2 (pravastatin at 10 mg kg-') and 3 (pravastatin at 20 mg kg-') respectively ( Figure 5 ). This suggests that pravastatin had stronger effects on adjacent hepatocytes than on enzymealtered lesions. However, its mechanism remains unclear.
Our present results show that administration of pravastatin suppresses hepatocarcinogenesis induced by NNM in rats and also significantly reduces amounts of membrane-associated p2lraS. These findings suggest that the suppression of hepatocarcinogenesis by pravastatin might be related to its inhibition of p2lras isoprenylation and its subsequent inhibition of cell proliferation and induction of apoptosis in neoplastic lesions.
